Stemchymal is under clinical development by Steminent Biotherapeutics and currently in Phase II for Spinocerebellar Ataxia (SCA). According to GlobalData, Phase II drugs for Spinocerebellar Ataxia (SCA) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Stemchymal’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Stemchymal overview
SBADSC-01 is under development for the treatment of neurodegenerative diseases such as polyqlutamine spinocerebellar ataxia. The therapeutic candidate is administered through intravenous and intra-articular route. The therapy constitutes adipose-derived mesenchymal stem cells. It is developed based on Stemchymal technology platform. The technology enables the isolation, processing and production of purified potent stem cell product from adipose tissues.
It was also under the development of Alzheimer's disease, acute on chronic liver failure (ACLF), acute liver failure, knee osteoarthritis, diabetes mellitus, Sequelae of arteriovenous malformation rupture and Parkinson's disease.
Steminent Biotherapeutics overview
Steminent Biotherapeutics operates within the clean technology sector of the energy and utilities industry, specifically focusing on farm efficient technologies within agriculture. It specializes in providing clean technology solutions to improve efficiency in farming.
For a complete picture of Stemchymal’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
